Acutus medical achieves eu mdr submission milestone in sale of left-heart access portfolio to medtronic

Carlsbad, calif., dec. 21, 2022 (globe newswire) -- acutus medical, inc. (“acutus” or the “company”) (nasdaq: afib), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced that the company has achieved the second milestone under the asset purchase agreement with medtronic of its left-heart access portfolio with the submission for ce mark of this portfolio under european union (eu) medical device regulations (mdr). this milestone triggers a $17 million earnout payment from medtronic to acutus.
AFIB Ratings Summary
AFIB Quant Ranking